- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Mitomycin C solution approved for glaucoma
Mobius Therapeutics has received final approval from the FDA for use of its mitomycin C ophthalmic solution (Mitosol) in glaucoma surgery. The company can begin marketing and producing the drug immediately.
St. Louis-Mobius Therapeutics has received final approval from the FDA for use of its mitomycin C ophthalmic solution (Mitosol) in glaucoma surgery. The company can begin marketing and producing the drug immediately.
“The approval of [the solution] for use in glaucoma surgery represents the culmination of more than 5 years of work,” said Ed Timm, president of Mobius Therapeutics. “It will provide surgeons, hospitals, and patients with enhanced convenience, safety, and consistency in the surgical treatment of glaucoma.”
The antifibrotic agent delivery system enables a precise dose of mitomycin C to be delivered to ophthalmic surgeons for use in procedures without any change to their current technique, according to the company, which is awaiting decisions from the FDA regarding refractive and corneal indications for the solution.
For more articles in this issue of Ophthalmology Times eReport, click here.
